Tags : P-ll

Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for

Shots: The P-ll SERENITY study involves the assessing of Mirikizumab (200mg, 600mg, 1000mg) vs PBO in patients in the ratio of 2:1:1:2 with moderately to severely active CD. The P-II study includes 12wks. induction period and 40wks. continued treatment period, evaluating the safety and efficacy of multiple dosing regimens and two methods of administration @52wks. […]Read More

Amgen Report Five Year Data of Aimovig (erenumab-aooe) in Open-Label

Shots:   The OLE P-II study involves assessing of Aimovig monthly (70mg) vs PBO in 383 eligible adult patients with an episodic migraine for 12wks. 250 patients increasing their dosage to 140mg monthly after a protocol amendment to assess the long-term safety of the higher dose The results of the OLE study showed the therapy helped […]Read More